We are considered to have world renowned capabilities in maximising sustained release drug formulations through the application of our advanced drug delivery systems (ADDS) which are based on polylactic-co-glycolic acid (PLGA).

Scientists working in our Swissmedic accredited laboratories also have expertise in solubility improvement, nanosystems, innovative formulations (e.g. for vectorisation of cytotoxic drugs) and pegylation technologies to link complex peptides and proteins with other molecules for targeted drug delivery and controlled release.

These technologies have demonstrated in multiple commercial products that they can strengthen the competitive advantage of new chemical entities and biologics and extend the patent life therefore the life cycle of important drugs.